HC Wainwright Issues Pessimistic Forecast for FTH Earnings

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Equities researchers at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Sensei Biotherapeutics in a research report issued on Thursday, October 22nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($2.60) for the year, down from their prior forecast of ($2.37). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Sensei Biotherapeutics’ current full-year earnings is ($13.69) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics’ FY2029 earnings at ($2.61) EPS and FY2030 earnings at ($2.60) EPS.

A number of other brokerages have also recently issued reports on FTH. Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price for the company. JonesTrading started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Finally, Oppenheimer initiated coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $16.83 on Tuesday. The company has a 50-day simple moving average of $29.91. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The firm has a market cap of $434.89 million, a PE ratio of -0.12 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20.

Institutional Trading of Sensei Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics in the 2nd quarter valued at $307,000. Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth $3,610,000. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics during the first quarter worth $22,758,000. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.